TrialJournal of travel medicine2024

A randomized, double-blinded Phase 3 study to demonstrate lot-to-lot consistency and to confirm immunogenicity and safety of the live-attenuated chikungunya virus vaccine candidate VLA1553 in healthy adults†.

Robert McMahon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.